Drugs Made In America Acquisition DMII
NASDAQ DMII
$10.14 +0.02 (+0.20%)
At close: Aug 20, 2026 · 4:00 PM EDT

Drugs Made In America Acquisition (DMII) Notes Payables (2024)

Drugs Made In America Acquisition (DMII) posted quarterly Notes Payables of $250100.0 for Q4 2024.

Drugs Made In America Acquisition (DMII) Notes Payables (2024) Analysis & Trends

Drugs Made In America Acquisition (DMII) has reported Notes Payables for 1 consecutive years, with $250100.0 the latest figure, recorded in Q4 2024.

  • In Q4 2024, Notes Payables changed N/A year-over-year to $250100.0; the TTM figure through Dec 2024 stood at $250100.0 (changed N/A YoY), while the FY2024 annual figure was $250100.0, changed N/A from the prior year.
  • Notes Payables held at $250100.0 in Q4 2024 per DMII's latest filing.
  • Across five years, Notes Payables topped out at $250100.0 in Q4 2024 and bottomed at $250100.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Launch Two Acquisition 557.86 Mn 557.86 Mn -
2 Drugs Made In America Acquisition 507.00 Mn 507.00 Mn -
3 Cantor Equity Partners IV 467.55 Mn 467.55 Mn -
4 GP-Act III Acquisition 401.06 Mn 401.06 Mn -
5 Aldel Financial 397.49 Mn 397.49 Mn -
6 Gores Holdings X 381.05 Mn 380.85 Mn -
7 Agriculture & Natural Solutions Acquisition 377.29 Mn 377.04 Mn -
8 Blue Water Acquisition Corp. III 342.12 Mn 342.08 Mn -
9 Berto Acquisition 313.96 Mn 313.81 Mn -
10 New Providence Acquisition Corp. III 313.81 Mn 313.81 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2024 250,100.00